Results 41 to 50 of about 756,852 (217)
Emerging Drugs for Generalized Myasthenia Gravis
Canadian Journal of Health Technologies, 2022 Horizon Scan reports provide brief summaries of information regarding new and emerging health technologies. These technologies are identified through the CADTH Horizon Scanning Service as topics of potential interest to health care decision-makers in Canada.
Sarah Ndegwa, Monika Mierzwinski-Urban
openaire +2 more sources
Smaller is better: nanobodies meet NMR
FEBS Letters, EarlyView.Nanobodies are single‐domain antigen‐binding fragments derived from camelid heavy chain antibodies. Their small size, high stability, and exceptional specificity make nanobodies uniquely useful probes for NMR studies of protein dynamics, transient conformational states, and protein–protein interactions.
Oleg Y. Dmitriev
wiley +1 more source
, 2018 Ocular symptoms and signs are the most common clinical manifestation of myasthenia gravis (MG). Paradoxically, however, the ocular aspects of myasthenia are the least well studied and understood.
Michael Benatar +3 more
core +1 more source
Total drug treatment and comorbidity in myasthenia gravis: a population-based cohort study [PDF]
, 2014 Background and purpose: Comorbidity in myasthenia gravis (MG) is important for diagnosis, treatment and prognosis. Disease complexity was assessed by examining total drug treatment, immune therapy and comorbidity in a complete national MG cohort. Methods:
A. Engeland +7 more
core +1 more source
Journal of Clinical Neurology, 2021 A major concern with ocular myasthenia gravis (MG) is the potential conversion to generalized MG. This study was conducted to determine if the repetitive nerve stimulation (RNS) test could predict the conversion from ocular to generalized MG.The RNS test was conducted in a consistent manner on five muscles in the face and limbs in every patient ...
Ki Hoon Kim +2 more
openaire +3 more sources
Inebilizumab in AQP4‐Seropositive NMOSD: One‐Year Follow‐Up From a Multicenter, Real‐World Study
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Real‐world evidence on inebilizumab among neuromyelitis optica spectrum disorder (NMOSD) patients is lacking. This study assessed inebilizumab among Chinese patients with aquaporin 4 autoantibody (AQP4‐IgG)‐seropositive NMOSD in a real‐world setting.
Mengcui Gui +10 more
wiley +1 more source
Frontiers in Neurology, 2021 Objectives: Myasthenia gravis (MG) is an immune-mediated neuromuscular disorder responsive to immunomodulatory treatments. 10–20% of MGs are not responsive to conventional first-line therapies.
Farzad Fatehi +13 more
doaj +1 more source
Autoimmune Comorbidities as Modifiers of Phenotypic Heterogeneity in Facioscapulohumeral Dystrophy
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Facioscapulohumeral dystrophy type 1 (FSHD1) shows clinical heterogeneity that is only partly explained by D4Z4 repeat unit (RU) size. Although immune and inflammatory mechanisms may contribute to disease variability, the prevalence and clinical impact of autoimmune diseases in FSHD remain unclear.
Jonathan Pini +9 more
wiley +1 more source
Thymoma with Myasthenia Gravis in Adolescent [PDF]
, 2011 Thymomas are exceedingly rare in the first 20 years of life, Thymic lesions comprise approximately 2–3% of all pediatric mediastinal tumors and include thymic cysts, hyperplasia, carcinoma, and thymomas.
Shetty, Prasad K +7 more
core
Correction to: Eculizumab: A Review in Generalized Myasthenia Gravis [PDF]
Drugs, 2018 The article Eculizumab: A Review in Generalized Myasthenia Gravis, written by Sohita Dhillon, was originally published Online First without open access.
openaire +2 more sources